|

Enzalutamide Clinical Trials

49 actively recruiting trials across 28 locations

▼ -1 trial since May 2026

Also known as: ASP9785, MDV 3100, MDV-3100, MDV3100, Radical prostatectomy +4 more

Pipeline

Phase 1: 10Phase 2: 21Phase 3: 8Phase 1/2: 8

Top Sponsors

  • Novartis Pharmaceuticals4
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
  • Pfizer3
  • Merck Sharp & Dohme LLC3
  • Memorial Sloan Kettering Cancer Center2

Indications

  • Cancer49
  • Prostate Cancer12
  • Metastatic Castration-resistant Prostate Cancer10
  • Metastatic Hormone-sensitive Prostate Cancer3
  • Prostatic Neoplasms, Castration-Resistant3

Other6 trials

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Phase 1
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Phase 2
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase 1/2

Tucson, Arizona5 trials

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 111

Phase 1/2
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Arizona Urology Specialists

Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Banner-University Medical Center Tucson

Phase 1
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The University of Arizona Cancer Center - North Campus ( Site 0073)

Phase 3
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Banner University Medical Center - Tucson

Phase 2

Chicago, Illinois4 trials

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

University of Chicago Comprehensive Cancer Center

Phase 2
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Northwestern University

Phase 1
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rush University

Phase 1/2

Los Angeles, California3 trials

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

UCLA Hematology & Oncology ( Site 0003)

Phase 1/2
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

University of California, Los Angeles

Phase 2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

California Research Institute

Phase 2

Birmingham, Alabama2 trials

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

University of Alabama at Birmingham

Phase 2
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Central Alabama Research

Phase 3

Huntsville, Alabama2 trials

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Clearview Cancer Institute (Crestwood)

Phase 3

Anchorage, Alaska2 trials

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Site US10052

Phase 2
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3

Orange, California2 trials

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Chao Family Comprehensive Cancer Centre

Phase 3

Baltimore, Maryland2 trials

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

Phase 2
The COSMYC Trial (COmbined Suppression of MYC)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Houston, Texas2 trials

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M D Anderson Cancer Center

Phase 2

Dothan, Alabama1 trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Site

Phase 3

Chandler, Arizona1 trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Ironwood Cancer & Research Centers

Phase 3

Phoenix, Arizona1 trial

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2

Duarte, California1 trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

City of Hope National Medical Center

Phase 1

La Jolla, California1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

University of California San Diego - Moores Cancer Center

Phase 2

San Diego, California1 trial

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

University of California, San Diego (UCSD)

Phase 2

San Francisco, California1 trial

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

UCSF

Phase 2

New Haven, Connecticut1 trial

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Yale University (Data Collection Only)

Phase 1/2

Sarasota, Florida1 trial

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Tampa, Florida1 trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Moffitt Cancer Center

Phase 2

Atlanta, Georgia1 trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Winship Cancer Institute of Emory University

Phase 1/2

Bethesda, Maryland1 trial

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

National Institutes of Health Clinical Center

Phase 2

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

New York, New York1 trial

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Weill Cornell Medicine/NewYork-Presbyterian Hospital

Phase 1

Cleveland, Ohio1 trial

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company

Portland, Oregon1 trial

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

VA Portland Healthcare System

Phase 2

Dallas, Texas1 trial

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Mary Crowley Cancer Research

Phase 1

El Paso, Texas1 trial

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Rio Grande Urology

Phase 1/2

Seattle, Washington1 trial

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.